Panobinostat’s Questionable Magnitude Of Benefit Can’t Outweigh Toxicities, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis shouldn’t give up on drug for relapsed multiple myeloma, FDA’s Oncologic Drugs Advisory Committee says, even as panel votes against approval based on progression-free survival data.
You may also be interested in...
Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
One Down, Two To Go: Pfizer/BioNTech Booster Decision Creates Pressure For More Extra Shot Authorizations
Inequity created by limiting the mRNA vaccine’s third dose to only those individuals who received a primary series of the same vaccine, as well as resulting operational complexities, warrant consideration of a mix-and-match approach with Moderna and J&J products, CDC advisors say; however, FDA appears most focused on vetting manufacturer-specific data on homologous boosting.
Pfizer COVID Booster Recommendations From CDC Panel Narrower Than FDA's EUA
Advisory Committee on Immunization Practices fails to pass an interim recommendation endorsing third dose of vaccine in health care workers and others at risk of occupational or institutional exposure, with panelists raising concern that the target population was overly broad.